Peptides by condition · Brain and nerves
Peptides studied for Alzheimer’s disease and dementia
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 9 study pages on Alzheimer’s disease and dementia: 2 in people (all meta-analyses or randomized trials), and 6 in animals and 1 in cells. They studied 6 compounds, with this many study pages each: Semaglutide (oral) 1, Cerebrolysin 1, P21 3, Dihexa 2, Vesugen 1 and Thymosin Beta-4 1.
What the research on Alzheimer’s disease and dementia looks like
Read the design before any result. Of these 9 studies, 1 was done on cells in a dish, 6 were in animals and 2 were in people, the largest with 3,808 people. A finding in cells or animals is where research starts, and many such findings do not hold up in people.
Alzheimer’s disease slowly destroys memory and thinking, and no medicine yet stops it. Most of the peptide research on it was done in rodents, in mice bred to build up the proteins amyloid and tau or in old rats, and in brain tissue grown in a dish. Only a small share was tested in people with the disease.
Trials in people score memory and thinking on standard tests and a clinician’s rating of overall change over months. Animal studies use maze tests and measure amyloid, tau and the connections between nerve cells.
Results in Alzheimer’s mice have a long record of not carrying over to people, so the design of each study matters more than its headline. The largest trials in people are the strongest test.
The 9 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Semaglutide (oral)
1 in peopleFor Alzheimer’s disease and dementia, 1 of our study pages is filed under Semaglutide (oral): 1 randomized trial in people. It enrolled 3,808 people and was published in 2026, in Lancet.
FDA-approved for other uses, not for Alzheimer’s disease and dementia: Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus).
- Randomized trial in people · 3,808 people · 2026Semaglutide (oral) did not slow early Alzheimer's in evoke trials
Cerebrolysin
1 in peopleFor Alzheimer’s disease and dementia, 1 of our study pages is filed under Cerebrolysin: 1 meta-analysis in people. It was published in 2015, in Dement Geriatr Cogn Disord, and our page does not give its size.
Cerebrolysin has no FDA-approved product: Drugs@FDA lists no application for it.
- Meta-analysis in people · 2015Cerebrolysin beat placebo on global change in Alzheimer's at 6 months
P21
3 in animalsFor Alzheimer’s disease and dementia, 3 of our study pages are filed under P21: 3 animal studies (mice and rats). None of them is in people. They were published from 2014 to 2020, in Alzheimers Res Ther, J Alzheimers Dis and Neurobiol Dis.
P21 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2020P21 in early life rescued Alzheimer-like deficits in mice
- Animal study in rats · 2015P21: lowered tau in the brain and spinal fluid of aged rats
- Animal study in mice · 2014P21 reduced tau buildup and cognitive deficits in Alzheimer's mice
Dihexa
2 in animalsFor Alzheimer’s disease and dementia, 2 of our study pages are filed under Dihexa: 2 animal studies (mice and rats). None of them is in people. They were published from 2013 to 2021, in Brain Sci and J Pharmacol Exp Ther.
Dihexa has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2021Dihexa restored spatial learning and memory in APP/PS1 mice
- Animal study in rats · 2013Dihexa showed antidementia activity in scopolamine and aged rat models
Vesugen
1 in animalsFor Alzheimer’s disease and dementia, 1 of our study pages is filed under Vesugen: 1 animal study (mice). It was published in 2021, in Pharmaceuticals (Basel).
Vesugen has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2021Vesugen (KED) prevented dendritic spine loss in Alzheimer's mice
Thymosin Beta-4
1 in cellsFor Alzheimer’s disease and dementia, 1 of our study pages is filed under Thymosin Beta-4: 1 cell study (human brain organoids). It was published in 2025, in Stem Cell Reports.
Thymosin beta-4 has no FDA-approved product: Drugs@FDA lists no application for it.
- Cell study in human brain organoids · 2025Thymosin beta-4 rescued AD-linked defects in human brain organoids
Side by side
For the 6 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Semaglutide (oral) | 1 | 0 | 3,808 | Approved for other uses |
| Cerebrolysin | 1 | 0 | — | Not approved |
| P21 | 0 | 3 | — | Not approved |
| Dihexa | 0 | 2 | — | Not approved |
| Vesugen | 0 | 1 | — | Not approved |
| Thymosin Beta-4 | 0 | 1 | — | Not approved |
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 3,808
- FDA
- Approved for other uses
- In people
- 1
- Animals or cells
- 0
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 3
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 2
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsThe trials tested only the 14 mg flexible dose of the oral form, in people with early, amyloid-confirmed Alzheimer's, and only 54 (2.8%) people in evoke+ had small vessel pathology. Both trials were stopped because of the negative result, and they were funded by Novo Nordisk.
- Cerebrolysin beat placebo on global change in Alzheimer's at 6 monthsThe pooled results cover two time points, 4 weeks and 6 months, and mix individual patient data with published group results across 6 trials. The cognitive benefit seen at 4 weeks was not statistically significant at 6 months.
- P21: lowered tau in the brain and spinal fluid of aged ratsThis was done in rats, so it does not show the same effect in people. The study measured tau and amyloid markers, not memory or other signs of dementia, and it did not test people with Alzheimer's disease.
- Dihexa restored spatial learning and memory in APP/PS1 miceThis is mouse work in one Alzheimer's research strain, so it does not show that Dihexa does the same in people. No humans were studied.
- Vesugen (KED) prevented dendritic spine loss in Alzheimer's miceThis was work in mice and in computer models, not a result in people, and the neuroplasticity effect was only a trend. The gene binding sites were predicted by modeling for EDR, not measured for KED.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for Alzheimer’s disease and dementia?
Our 9 study pages on Alzheimer’s disease and dementia are filed under 6 compounds, with this many each: Semaglutide (oral) 1, Cerebrolysin 1, P21 3, Dihexa 2, Vesugen 1 and Thymosin Beta-4 1. P21 has the most.
Have any been tested in people with Alzheimer’s disease and dementia?
Yes: 2 of the 9 were in people, all of them meta-analyses or randomized trials (Semaglutide (oral) and Cerebrolysin). The largest enrolled 3,808 people: “Semaglutide (oral) did not slow early Alzheimer's in evoke trials” (2026).
Is any peptide FDA-approved for Alzheimer’s disease and dementia?
Not by the labels our status pages read: of the 6 compounds here with an FDA record, none has a use tied to Alzheimer’s disease and dementia. Semaglutide (oral) is FDA-approved for other uses.
How large were the studies in people on Alzheimer’s disease and dementia?
Of the 2 in people, 1 gives its size on our pages: 1 had 1,000 people or more. The largest, a randomized trial from 2026, enrolled 3,808.
What did the animal and cell studies on Alzheimer’s disease and dementia use?
6 animal studies (mice and rats) and 1 cell study (human brain organoids), filed under Dihexa, Vesugen, P21 and Thymosin Beta-4. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on Alzheimer’s disease and dementia here?
Of our study pages on Alzheimer’s disease and dementia, the newest is “Semaglutide (oral) did not slow early Alzheimer's in evoke trials”, a randomized trial in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.